Ra Pharmaceuticals’ (NASDAQ:RARX) “Buy” Rating Reiterated at SunTrust Banks

Ra Pharmaceuticals (NASDAQ:RARX)‘s stock had its “buy” rating restated by research analysts at SunTrust Banks in a research report issued to clients and investors on Thursday, March 15th.

A number of other equities analysts also recently issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price target (up previously from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday, December 4th. Credit Suisse Group reiterated an “outperform” rating and set a $16.00 price target on shares of Ra Pharmaceuticals in a research report on Thursday, January 18th. Royal Bank of Canada restated a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a research report on Tuesday, December 5th. Zacks Investment Research downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, ValuEngine downgraded Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $19.50.

How to Become a New Pot Stock Millionaire

Ra Pharmaceuticals stock remained flat at $$5.51 during midday trading on Thursday. The company had a trading volume of 187,313 shares, compared to its average volume of 259,768. The firm has a market capitalization of $177.90, a price-to-earnings ratio of -2.29 and a beta of 2.31. Ra Pharmaceuticals has a 12-month low of $4.78 and a 12-month high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Wednesday, March 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. research analysts predict that Ra Pharmaceuticals will post -2.16 EPS for the current year.

In other Ra Pharmaceuticals news, major shareholder Enterprise Associates 13 L. New bought 2,000,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was bought at an average price of $6.00 per share, with a total value of $12,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ra Capital Healthcare Fund Lp bought 2,500,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The shares were acquired at an average cost of $6.00 per share, with a total value of $15,000,000.00. The disclosure for this purchase can be found here. Company insiders own 14.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Paloma Partners Management Co acquired a new stake in Ra Pharmaceuticals during the fourth quarter worth $154,000. Two Sigma Investments LP acquired a new stake in Ra Pharmaceuticals during the fourth quarter worth $164,000. Ellington Management Group LLC acquired a new stake in Ra Pharmaceuticals during the fourth quarter worth $297,000. Goldman Sachs Group Inc. increased its stake in Ra Pharmaceuticals by 76.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,937 shares of the company’s stock worth $246,000 after acquiring an additional 12,516 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Ra Pharmaceuticals by 47.9% in the fourth quarter. BlackRock Inc. now owns 952,580 shares of the company’s stock valued at $8,097,000 after buying an additional 308,452 shares in the last quarter. 47.86% of the stock is owned by institutional investors.

WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/suntrust-banks-reiterates-buy-rating-for-ra-pharmaceuticals-rarx.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply